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Cyclophosphamide in severe steroid-resistant 
bronchiolitis obliterans organizing pneumonia 
I. F. PURCELL, S. J. BOURKE AND S. M. MARSHALL 
Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE, U.K. 
A patient receiving carbamazepine and imipramine presented with severe bronchiolitis obliterans 
organizing pneumonia (BOOP). He developed progressive respiratory failure in spite of high-dose steroid 
treatment. Cyclophosphamide was given as adjunctive therapy, and a rapid improvement was seen. The 
authors suggest hat an early therapeutic trial of cyclophosphamide should be considered in patients with 
BOOP who fail to respond to steroids. 
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Introduction 
Bronchiolitis obliterans organizing pneumonia 
(BOOP) is increasingly recognized as a distinct 
clinicopathological entity (1). A rapid response 
to corticosteroid treatment and a generally 
favourable outcome were characteristic features 
of the initial description of BOOP (1,2). How- 
ever, with increasing experience of the clinical 
spectrum of this disease, it is now recognized 
that some patients have rapidly-progressive dis- 
ease, which is refractory to steroids and associ- 
ated with a poor prognosis (3). The present case 
report describes the adjunctive use of cyclophos- 
phamide in a patient taking carbamazepine and 
imipramine who developed severe steroid- 
resistant BOOP. 
Case Summary 
A 49-year-old, non-smoking male presented with 
a 3-week history of progressive dyspnoea with 
malaise, anorexia, weight loss, sweats and a 
non-productive cough. Nine months previously, 
he had been commenced on imipramine 100 mg 
and carbamazepine 200 mg once daily for 
depression. He had not been exposed to known 
toxins or relevant respiratory antigens. On 
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examination, he was pyrexial (38.O”C) and had 
an erythematous rash over the trunk and limbs. 
He was tachypnoeic with symmetrically-reduced 
lung expansion and diffuse lung crackles. Exam- 
ination was otherwise normal with no signs of 
connective tissue disease. 
A chest radiograph demonstrated moderate 
bilateral symmetrical interstitial and alveolar 
shadowing most extensive at the lung bases. 
High-resolution computed tomography defined 
multiple areas of air-space consolidation with 
ground glass opacities but no hilar adenopathy 
(Plate 1). Arterial blood gas analysis on air 
showed PaO, 7.7 kPa and PaCO, 5.0 kPa. 
Forced expiratory volume in 1 s (FEV,) was 
1.70 1 (predicted 4.18 1) and functional vital 
capacity (FVC) 1.84 1 (predicted 5.24 1). He was 
too dyspnoeic for full spirometry. Serological 
tests for viruses, atypical organisms, hepatitis, 
human immunodeficiency virus (HIV), collagen 
vascular and autoimmune disease were negative. 
Avian and fungal precipitins were negative. 
Liver function tests were abnormal. Skin biopsy 
showed non-specific dermatitis. Fibre-optic 
bronchoscopy with transbronchial biopsy was 
performed. The biopsy specimen showed a 
patchy interstitial lymphocytic infiltrate with 
severe pneumocyte hyperplasia, the alveoli 
and alveolar ducts were filled with buds of 
fibroblastic tissue characteristic of BOOP. 
Prednisolone 1 mgkgg’day-’ (60 mg> 
was commenced, and imipramine and 
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PLATE 1. High-resolution computer tomogram of 
thorax performed at presentation showing ground 
glass opacities and interstitial shadowing. 
carbamazepine were discontinued. The patient’s 
condition continued to deteriorate with worsen- 
ing respiratory failure and progression of the 
radiographic shadowing over the next 3 weeks. 
At this time, an Rio, of 60% produced an 
arterial PaO, of 6.0 kPa and mechanical ven- 
tilation was considered. Cyclophosphamide 
150 mg day-’ was then added, and by Day 7 of 
this treatment, the patient’s condition had begun 
to improve. 
The patient made a dramatic recovery over the 
next 6 weeks. His arterial blood gas analysis on 
air showed PaO, 12.5 kPa and PaCO, 5.4 kPa. 
The FEV, was 2.84 1, FVC 3.17 1, diffus- 
ing capacity for carbon monoxide (DCO) 
3.14 mm01 min - ’ kPa -’ (27% predicted) and 
diffusing coefficient (KCO) 0.75 (48% predicted). 
The radiographic abnormalities had largely 
cleared, liver function had returned to normal 
and he was allowed home. 
Cyclophosphamide (150 mg day - ‘) and pred- 
nisolone were continued for 6 months. The pred- 
nisolone was reduced by 5 mg every 2 weeks. 
There was further improvement in lung function 
over this time, with FEV, rising to 4.89 1, FVC 
5.91 1, DC0 8.7 mmol min - ’ kPa - ’ (75% pre- 
dicted) and KC0 1.16 (75% predicted). There 
has been no relapse over 18 months on no 
treatment. 
Discussion 
The aetiology of BOOP is unknown, but a 
variety of reports have implicated several 
chemically-distinct drugs (1,4-S). Bronchiolitis 
obliterans organizing pneumonia has not been 
reported previously in association with imi- 
pramine or carbamazepine, and evidence here 
for an aetiological association is not clear. The 
present patient did not improve on stopping the 
suspect drugs, as has been seen in some cases 
associated with acebutalol (6) and gold (7), but 
such improvement is not consistently seen in 
drug-related BOOP (4-7). An erythematous rash 
is described in antibiotic-associated BOOP (4), 
and interestingly, the present patient’s rash 
improved after the addition of cyclophospha- 
mide in parallel with his respiratory status. In 
cases of BOOP it appears wise to discontinue 
any pre-existing drug treatment. 
Initial reports suggested that more than 80% 
of patients with BOOP showed rapid and 
complete resolution of the disease on steroids, 
although relapse could occur as the dose was 
reduced (2,9). However, patients are now being 
recognized who demonstrate a more aggressive 
clinical course with rapidly-progressive disease 
which is unresponsive to steroids and associated 
with a high mortality (3). The present patient 
was given prednisolone at an adequate dose 
(9,lO) for a duration within which clear improve- 
ment would be seen in the vast majority of 
patients (10,ll). Instead, he deteriorated alarm- 
ingly and the authors considered him to be 
steroid resistant. In such cases, a number of 
treatments have been tried including plas- 
mapheresis, immunoglobulins and cyclophos- 
phamide (3,lO). These treatments have usually 
been tried late in the course of the disease 
and have generally been unsuccessful; however, 
the present patient showed a dramatic response 
after the addition of cyclophosphamide. The 
therapeutic role of cyclophosphamide in this 
case is unproven because the possibility can 
not be dismissed that the improvement was 
due simply to a further week of prednisolone 
therapy, and it is not known whether the com- 
bination with prednisolone is necessary for effi- 
cacy. Definitive recommendations for treatment 
could only come from controlled study on 
groups of patients, but the authors’ experience 
suggests that cyclophosphamide can be given 
safely in BOOP, and an early therapeutic trial 
should be considered in patients who fail to 
respond to steroids. 
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